Ask AI
ProCE Banner Activity

Optimizing Patient-Centered Care for Relapsed/Refractory CLL With the Latest Evidence and Guideline Updates: Precision Education with Real-world Insights

Slideset

Downloadable slides on the latest clinical evidence and guideline recommendations for relapsed/refractory CLL and management of treatment-related toxicities.

Released: April 21, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with the CLL Society.

ProCE Banner

Supporters

Supported by an educational grant from Lilly.

Lilly

Partners

CLL Society

ProCE Banner

Target Audience

This activity has been designed to meet the educational needs of community hematologists/oncologists, nurse practitioners, physician associates, nurses, pharmacists, and other healthcare professionals who are part of the multidisciplinary care team for people with R/R CLL/SLL.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Plan individualized treatment sequences leveraging novel targeted and/or cellular therapies for eligible patients with R/R CLL to optimize clinical benefit and quality of life in alignment with patient preferences, clinical evidence, and current guidelines

  • Employ guideline- and expert-recommended biomarker testing to assess patients with R/R CLL for acquired resistance mutations to guide therapy selection and optimal sequencing

  • Assess emerging clinical evidence for novel targeted and cellular therapies and the clinical implications for management of R/R CLL

  • Apply shared decision-making and communication strategies to support patient quality of life and engagement in care for R/R CLL